Smarter. Stronger. Together. Progressing Towar... - CLL Support

CLL Support

22,609 members38,830 posts

Smarter. Stronger. Together. Progressing Toward Optimal CLL Care Through Healthcare Professional and Patient Education

lankisterguy profile image
lankisterguyVolunteer
0 Replies

clinicaloptions.com/oncolog...?

-

This is an educational series intended for medical professionals, but patients that understand MedSpeak should be able to learn from it. It is sponsored by several organizations including the CLL Society.

-

In this CME/CE-certified activity, review the latest multidisciplinary strategies for optimizing care of patients with CLL, including discussion of effective patient education on treatment selection and toxicity management.

Discussion topics include:

• Evolving CLL Treatment Recommendations

• Individualizing Frontline Therapy for Patients With Chronic Lymphocytic Leukemia: Putting Evidence Into Practice

• Addressing Patient Knowledge Gaps, Concerns, and Misperceptions About CLL

• Assessing Measurable Residual Disease in Chronic Lymphocytic Leukemia

• Multidisciplinary Perspectives on Managing Adverse Events With BCL-2 and PI3K Inhibitors in CLL

• Multidisciplinary Perspectives on CLL-Related Symptoms and Managing Adverse Events With BTK Inhibitors

-

Len

Written by
lankisterguy profile image
lankisterguy
Volunteer
To view profiles and participate in discussions please or .

You may also like...

Mode of Progression After Frontline Treatment Predicts Clinical Outcomes in Patients With CLL

particular in unfit patients with CLL. This might help physicians in managing their patients and...

Zanubrutinib vs. Ibrutinib Patient Power Video by Dr. Jennifer Brown MD PHD

Dana Farber, updates our chronic lymphocytic leukemia (CLL) patients on the latest from the 2022...

Imbruvica adverse effects.

com/insights/b-cell-malignancies/adverse-events-of-ibrutinib-in-chronic-lymphocytic-leukemia

CLL Videos with CLL Expert at the Mayo Clinic... Dr. Tait Shanafelt

Chronic lymphocytic leukemia, or CLL, is a cancer of the blood and bone marrow. In this video, Dr....

EHA 2022: Outcomes Following Treatment With a Covalent BTK and BCL2 Inhibitor

nt-btk-and-bcl2-inhibitor-among-patients-with-chronic-lymphocytic-leukemia-cll-small-lymphocytic-lym